US FDA Approves to Market Lupin's Generic Dovonex Scalp Solution

Lupin has received final approval from the US Food and Drug Administration (FDA) to market calcipotriene topical solution, 0.005% (scalp solution), a generic version of Dovonex scalp solution, 0.005% of Leo Pharmaceutical Products Ltd.

Lupin's calcipotriene topical solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. Calcipotriene topical solution had annual sales of approximately USD 5.9 million in the US.

With this approval, Lupin scrip moved up by Rs. 10 to Rs. 890 in the morning session on BSE.